15.40Open15.40Pre Close0 Volume0 Open Interest95.00Strike Price0.00Turnover0.00%IV1.62%PremiumDec 6, 2024Expiry Date14.09Intrinsic Value100Multiplier2DDays to Expiry1.31Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.76Leverage Ratio--Theta--Rho--Eff Leverage--Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet